Nah, the only reason everyone is still here is the FDA pulled Amarin's SPA 10 years ago. That set up the opportunity to have a minor indication come off regulatory exclusivity and opening up the doors for Generics to go after the drug just when Reduce It label was getting approved. That is 100% product lifecycle management f-up by Amarin. They should have sued the FDA to delay exclusivity while Reduce It (that they demanded) was being completed so Reduce It got the full NCE and not the NME.
Market Data 
Markets 
AI
